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1. Introduction  
In recent years, the Indian government has undertakn significant modifications in the 
Intellectual Property (IP) regime of the country. Some of the key elements of the modified 
policy having major implications for several sectors in the economy, especially the 
pharmaceutical, chemical, biotechnology and information technology related sectors. Given 
the changes in the IP regime, the competitive landscape of many of these sectors is 
undergoing a fundamental change in India. This has led to a realignment of business 
strategies by firms in these sectors in order to face the challenges thrown up by the changing 
regime, as companies which enjoyed protection under Indian IP laws will have to adapt to 
India's accession to WTO (TRIPS) norms in 2005. At the same time, globalization of the 
Indian economy is opening up new opportunities for firms in the country and they will need 
to build strategies to exploit the emerging opportunities. 
 
IP regimes in a country play an important role in fostering the direction and the quality of 
entrepreneurial innovation across all sectors of the economy. For example, an IP law that 
fosters incremental innovation can allow small busine ses to benefit by affording protection 
to small incremental improvements on existing intellectual property that can in turn be used 
by owners of the IP to move up the technological value chain. In addition, the IPR framework 
directly affects the ability of entrepreneurs to take advantage of commercial opportunities that 
require the existence of a suitable IP regime before commercial/service agreements can be 
reached with potential clients. Such market creating potential of the IPR framework can also 
impinge on the ability of small entrepreneurs to enter into IP intensive activities as 
subcontractors and licensees.  
 
While India has made its IP regime TRIPS compatible, it is not entirely clear if the new 
regime would facilitate the participation of Indian companies in the knowledge intensive 
global production and R&D networks and if it is appro riate for an economy that is expected 
to grow rapidly enlarging the demand for a variety of products and services. This paper 
explores these issues in the context of IT-electronics and pharmaceuticals- biotechnology 
sectors. It is built on the premise that ceteris paribus participation of Indian firms in IP 
creation and participation in knowledge intensive activities is desirable. If changes in 
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technology and global industrial structure are creating opportunities for such participation, IP 
policies should positively discriminate in favour of such participation. Similarly, if the 
domestic market for knowledge intensive activities is growing rapidly, policy makers should 
explore if tinkering with IP policies can facilitate the participation of local firms in this 
market. The paper argues that such possibilities exi t and some pro-active changes in IP 
policies are desirable.  
 
The rest of the paper is divided into four sections.  Section 2 summarizes the emerging 
opportunities in the pharmaceutical-biotech sector and explores areas where Indian firms can 
potentially participate. The next section undertakes a similar analysis for the IT-electronics 
sector. Section 4 reviews the existing IPR laws to evaluate if these laws can potentially 
constrain the exploitation of the emerging opportunities in these sectors by Indian firms.  The 
final section provides some concluding remarks. 
 
2. Emerging Entrepreneurial Opportunities in the Pharma-Biotech Sectors 
The innovation system in the pharmaceutical industry is very complex. The complexity of 
R&D, which is essentially science based, has been on the rise due to the emerging synergies 
in the research streams of conventional chemistry, biotechnology and information technology 
(IT). It is becoming increasingly important to integrate knowledge at various levels of 
research in biomedical sciences, pharmaceuticals and IT. Institutional factors are very 
important for such integration and coordination. For example, institutional coordination 
across disciplines between academic research labs, public sector research establishments, 
private industrial research units, pharmaceutical firms, CROs and hospitals will be critical for 
such integration to take place.  
 
2.1 Changes in Drug Discovery Systems  
Riding on the synergies between different disciplines, the drug discovery and 
commercialization processes are undergoing significant hange. The following developments 
are particularly important to understand the potential changes in the innovation system of the 
pharmaceutical industry (see Economist, 1998 and Jugmittag et al, 2000 for details):   
 
The shift from wet chemistry to bio-technology based processes for identifying/ developing a 
molecule or compound has reduced the economies of scale; 
Combinatorial chemistry has helped develop gene libraries that can be hired for screening 
resulting in significant reduction in the entry barriers in initial screening business; 
Computer aided development of molecular designs is u ed to filter molecules and compounds 
for testing with wet chemistry. This biotechnology-software interface has meant higher 
success rates and speedier selection of compounds; 
Actual drugs are being designed with the help of computers. Software are used to reduce 
uncertainty in drug development; 
New technologies in pre-clinical development are reducing the drug development cycle. For 
example, cassette dosing and simultaneous optimization of toxicity, bioavailability and 
pharmacokinetics has reduced the time required for clinical trials. Service firms have emerged 
to do such trials; 
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Computerized safety and efficacy trials conducted on patients avoid useless regimes to reduce 
number and size of trials. This saves time and money. These new technologies have also 
facilitated the emergence of contract research organization (CROs). 
 
Appendix I provides an overview of the drug discovery and development process today. This 
chart along with the changes listed above identifies a variety of entrepreneurial opportunities. 
Overall, these technological developments have created  situation where drug discovery and 
development may no more be dominated by large vertically integrated enterprises. Decline in 
entry barriers in several segments can lead to disintegration of this process. Given good 
access to software, biotechnology and wet chemistry based skills, many firms in India are 
well placed to occupy several spaces in this value chain. However, a favourable IPR regime 
and good implementation of the IP laws may be essential for these firms to participate in 
decentralized drug discovery & development process where several firms perform highly 
specialized tasks. This would be particularly so if the entry into these niches is innovation 
based or if it involves use of protected technologies. With the impending changes in the IPR 
regimes, Indian firms will need to identify their niches and create appropriate capabilities for 
occupying these niches. A favourable IPR regime combined with the above mentioned 
technological developments and the associated uncertainties might also lead to creation of 
networks and alliances between firms having diverse capabilities on the one hand and 
educational institutions & public sector entities on the other. 
 
2.2 Emerging Strategies for Pharmaceutical Firms 
These changes in the drug discovery processes and the emerging liberal policy environment 
will have significant implications for the innovation system in the pharmaceutical sector and 
for the strategies adopted by firms in this sector, especially small ones. Moreover, from the 
perspective of the transnational corporations, three strategic changes are expected to take 
place2: 
 
• FDI in overseas manufacturing may increase with special focus on contract 
manufacturing of drugs (even the ones that are still on patent); 
• More on more pharmaceutical firms may locate part of heir R&D activities in India 
through R&D centres or through outsourcing of technological activities; and  
• The research portfolio of MNCs may shift (at least marginally) in favour of diseases 
relevant for the developing countries, especially those that have large populations with 
reasonable ability to pay. Such a shift would require specialized skills of firms, 
individuals and R&D institutions in developing countries like India. 
 
Admittedly, the strategies that the MNCs would adopt f r countries like India will depend on 
a variety of factors, including the availability of skills and capabilities as well as the nature of 
regulation and competition in the host countries. A systematic exploration of these strategies 
and their linkages with regulation and the innovation system would be useful. A proactive 
regulatory structure can, in fact, facilitate the exploitation of these strategic opportunities by 
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Indian pharmaceutical, biotechnology and IT companies. An appropriate IP regime, for 
example, may not only help exploit the opportunities created by the changes in drug 
development technology and the emerging structure of the pharmaceutical and biotechnology 
sectors but also help respond effectively to the emrging R&D and production strategies of 
the MNCs. We may gain a great deal if India becomes a hub for R&D and manufacturing 
related sub-contracting in these sectors. Preliminary explorations suggest that pharmaceutical 
firms in India are exploring the following options (Table 1)3: 
 
• Develop new pharmaceutical products. So far, the trend is that firms find new chemical 
entities, patent them in major international markets, develop them up to a point and then 
license them to MNCs for further developments and clinical trials (Grow and sell 
strategy); 
• Focus R&D on drug delivery mechanisms, dosage forms and bio-enhancers to improve 
the efficacy of existing patented drugs. Once this is achieved, cross licensing possibilities 
with the patent holder of the drugs that are affected by these inventions can be explored; 
• Focus on process R&D for patented drugs to acquire process patents and explore cross-
licensing/ licensing options. These process inventions are also very useful once the drug 
gets off patent; 
• Build alliances with biotech and IT firms and also with educational institutions to develop 
new technologies for pharmaceutical research. IT firms are also gradually entering into 
the health domain; 
• Focus on contract manufacturing of patented drugs; 
• Focus on drugs, which are going to be off patent in he near future. This strategy is 
particularly being followed to enter developed country markets as soon as the relevant 
patent expires;   
• Produce drugs that are off patent today; and 
• Combine some of these strategies with co-marketing/marketing arrangements. 
 
Table 1 
Emerging Strategies of Indian Pharmaceutical Firms 
Strategy Companies 
A. Supply Partner/Sourcing Base  
A1. API, Intermediates, Dosage Forms Cipla, Biocon, NPL, Dishman, Cadila 
A2. Contract Research & manufacturing  
A21. Contract manufacturing (CMO) Shasun, Jubilant, Dishman, Cadila, Syngene 
A22. Contract Research (CRO) Vimta labs, Clingine 
B. Generic Manufacturing  
B1. Para II/III Generics Ranbaxy, Dr Reddy’s, Sun Pharma, Wockhart, Cadila 
B2.Patent Challengers Ranbaxy, Dr Reddy’s, Sun Pharma 
C. Innovator  
C1. New Drug Delivery System (NDDS) Ranbaxy, Cipla, Sun Pharma 
C2. New Chemical Entity (NCE) Research Ranbaxy, Dr Reddy’s, Sun Pharma, Glenmark 
Source: IVCJ (2006), p. 23 
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That the scope for contract manufacturing is high can be gauged by the fact that India has 
more than 70 FDA approved drug manufacturing plants d over 200 Good Manufacturing 
(GMP) compliant manufacturing plants (IVCJ, 2006). It is evident that the IP regime and its 
implementation will affect most of these strategies. This will be particularly the case with 
respect to product patenting, data exclusivity etc.As mentioned, within the first strategy, the 
firms may have different options. The inventing company may not manufacture the product it 
has developed; it may not even conduct expensive trials required before commercialization of 
the drug. The company can grow and sell its product to another company that will conduct 
trials, manufacture and commercialize the product. Apparently, the licensing arrangements 
are proliferating because the costs of taking an invention from conception to market are 
escalating. Laboratory work and a series of trials and pilot projects follow basic research. 
Only when the trials are successful, can the drug be commercialized. At each stage, the costs 
and risks increase exponentially and so it make sense for Indian firms, who have limited 
resources but an abundance of low-cost and highly trained scientists, to focus on basic results 
and license the results. Grow and sell strategy can potentially exploit relatively inexpensive 
research skills of Indian scientists without taking undue risks. Very few firms may, however, 
have the product development and licensing skills and capabilities to implement this strategy. 
Exploitation of relatively inexpensive research skill  and process capabilities that have been 
acquired over the years may be more feasible, if a firms wishes to opt for an R&D intensive 
strategy. The other strategies to exploit emerging niches in drug discovery, drug delivery, 
process innovations etc. may be more relevant for relatively smaller enterprises.  
 
Unfortunately, no systematic assessment has been made of the links between these strategies 
and IP regimes. A detailed analysis of the IP needs for the exploitation of such opportunities 
is critical.  However, apart of the examples listed in Table 1 and  Appendix II, a few more 
examples suggest that Indian firms are exploiting some of the emerging opportunities and 
benefiting from them: 
 
 Matrix Laboratories developed a non-infringing process for the blockbuster anti-depressant, the 
$1.5-billion Citalopram. Lundbeck, a Danish pharma company and the Originator, made a $40-
million offer - nearly half of Matrix's annual revenues - for this manufacturing process. 
 Hyderabad-based Avon Organics developed the biotechnology process for pseudoephedrine (an 
off-patent raw material cold formulations and syrups) and its derivatives, with GlaxoSmithKline 
(GSK). Ever since Avon changed its strategy from a general API (active pharmaceutical 
ingredient) supplier to a friendly API supplier in 1996, its revenues have grown from Rs. 16 crore 
to Rs. 90 crore today. 
 Moreover, while the jury on whether a new use or dosage form (formulation) patent extend the 
term of the patent granted on the original molecule is still out (see discussion in Section 4), some 
Indian firms have started to benefit from it. Bayer patented ciprofloxacin in 1983 and its patent 
expired in 2003. As such others were free to research nd study the molecule. The research by 
Ranbaxy led to the development of a once-a-day oral dosage form, which increases patient 
compliance and convenience. Bayer bought the product development and global marketing rights 




Most of the research-based firms believe that a more st ingent IPR system will create newer 
opportunities for the Indian firms. It is argued that during the pre-TRIPS period, the Indian pharma 
industry developed unique skills in chemistry and biochemistry. Now, Indian companies can 
compete effectively with global majors in developing ew salts, new derivatives, new uses, new 
dosages and new delivery systems. In fact, according to the PCT database, Indian companies have 
filed approximately 4200 applications. Of these applications 55 per cent are for pharmaceutical 
incremental innovations. For instance, Ranbaxy has filed 239 patent applications of which 122 are 
for derivatives, formulations, compositions and new dosage forms. Most of Ranbaxy patent 
applications are for incremental innovations 
 
2.3 The Biotech Factor 
The above-mentioned research based opportunities have multiplied with the growth of 
biotechnology in India. According to some estimates, there are about 800 biotech related 
companies, with 96 firms exclusively working with biotechnology. With beginnings in 
fermentation and enzyme production, the industry has now grown to about $ 1.07billion and 
covers new drug discovery, bio-informatics, clinical research and synthetic chemistry. About 
230 biotech-based drugs are already in the market covering 13 therapeutic segments (IVCJ, 
2006; 28).  Moreover, genomic research, bio-generics and stem cell research are adding fresh 
opportunities for growth. 
 
2.4 Convergence of Pharma-Biotech and IT Technologies  
With technological change, several new opportunities for IT firms to work on the boundaries 
of other sectors like the pharmaceutical, biotechnology, and auto are becoming available. It is 
becoming increasingly important to integrate knowledg  at various levels of research in 
biomedical sciences, pharmaceuticals, and IT. Riding o  the synergies between different 
disciplines, the drug discovery and commercialization processes are undergoing significant 
change. Based on the changes in the drug discovery systems discussed earlier, several 
opportunities seem promising. Increasing use of combinatorial chemistry to develop gene 
libraries that can be hired for IT based screening will result in significant reduction in the 
entry barriers in initial screening business. Besides, computer aided drug design, use of IT in 
pre-clinical trials and computerized safety and efficacy trials also provided new 
entrepreneurial opportunities. All these domains are very IP intensive and would require a 
more proactive participation of Indian firms in IP protection. This will obviously lead to 
enhanced participation of these firms in IP generation and creation. There is evidence to show 
that Indian IT firms are increasingly exploiting these domains as well.4  
 
3. Emerging Entrepreneurial in the Indian IT and Electronics Industries  
The Indian IT industry is undergoing a major change. D spite concerns on the contrary, one 
can see a shift towards more value added services, an emerging specialization in embedded 
                                               
4 Strand Genomics, a spin out firm from a well-known institute of science education (Indian Institute of Science, 
Bangalore) is a prime example of this trend. Other firms active in this domain include Agilent Technologies 
(Life Sciences and Chemical Analysis), Wipro Health Scien e, SysArris Software and Kshema Technologies. 
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software and even a marginal shift towards products. The opportunities for IT firms to work 
on the boundaries of the pharmaceutical and biotechnology sectors have already been 
highlighted. There is also a belief that in future, major market growth in IT would take place 
in Asia, especially in India and China. Consequently, firms will need to create IT products 
that satisfy the specific needs of these markets. When this trend picks up, the Indian IT firms 
would find themselves much closer to the market and would be able to respond better to the 
emerging market needs than firms that are located elsewhere. One of the problems, Indian 
firms have faced vis-à-vis product development has been the "distance from the market". 
Lack of proximity to the large western markets where the IT products currently sell has put 
them at a disadvantage. Such a disadvantage may get reduced if the local markets pick up. 
The IP regime needs for the sector need to be seen in this context.  
 
Technologies underlying the IT industry are changing very rapidly. In many instances, these 
technological changes bring in possibilities of a change in the global industrial structure. 
While there are many instances of this type, we will focus on a few to highlight the potential 
impact on IPR needs of Indian IT firms. 
 
3.1 Insights from Embedded Software/Services Industry5  
New technologies have modified global production networks significantly in the area of 
semi-conductors in recent years. Similarly, the munificence of IT based technologies across a 
variety of sectors has spawned several new technological and economic opportunities.  It is 
argued that changes in these technologies and the associ ted changes in the industrial 
structures are likely to throw up new entrepreneurial opportunities for Indian IT firms which 
might require a different perspective on IP related issues. 
 
With the advent of System on Chip (SoC) integration in this industry, the strategic options of 
firms have changed.6  As SoCs become larger and more complex, it will become difficult for 
firms to remain competitive in all the functional design elements that are being integrated into 
the SoC. An emerging solution for this problem is the fast growing market of design modules 
(DM) licensed out by small, specialized firms. This change can potentially ‘disintegrate’ the 
semi-conductor industry providing niche opportunities for small firms. According to Linden 
and Somaya (2003), this shift can be quite significant: 
 
The emerging SoC-based industry structure typifies the historical shifting between 
integrated and ever more fragmented organizational modes of producti n in the electronics 
industry. Just as specialization in components proliferated in the PCB-based electronic 
systems, the SoC era is showing signs of industry fragmentatio  driven by specialization in 
the disembodied semiconductor designs that are being licensed between firms. (Linden and 
Somaya, 2003). 
 
Recent studies (see, for example, Bhuyan, 2002) and the information summarized in 
Appendix II show that many Indian firms are already active in this emerging domain and are 
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participating in the emerging networks of SoC creation. India may have missed the IC 
manufacturing opportunity; it sure can exploit this new opportunity. But, this will require 
sharper focus on IP and a more active participation in standards creation, as that will drive the 
creation of markets in this sector.7 
 
The embedded devices ecosystem consists of firms in embedded products and services 
segments. This consists of OEM’s such as Nokia and IBM that design and produce products 
like mobile phones and laptops. These products contain features (e.g., computing, graphical 
image processing, audio and speech encoding/delivery, and wireless connectivity) that are 
powered by semiconductor chipsets (platforms) developed by large MNCs like Texas 
Instruments, Intel, Siemens etc. Embedded software applications are developed to leverage 
the power of the processor platform for customer spcific applications. There exist electronic 
design automation firms (EDA) like Cadence and Synopsis, which create software tools to 
accelerate the hardware and embedded application design tasks. Finally, there are services 
firms that leverage their knowledge of the embedded software tools, EDA tools, processor 
platform architecture, and customer requirements to develop embedded software applications 
for their customers. Indian firms are essentially located in the last segment and provide 
design services. These firms include Wipro, Sasken, Mindtree Consulting, Tata Elxsi, HCL 
Technologies, etc. (Goyal and Sharma, 2004). 
 
Within design services, three levels can be distinguished: device level, module level and 
system level. Within device level, design services provided by Indian firms areb oadly 
divided into: (i) front-end design, (ii) design verification, (iii) physical/back-end design and 
(iv) chip deployment services. Of these, the bulk of the work coming the way of Indian 
service firms is in design verification. Recently, Indian firms have moved up the value chain, 
into front-end design of complex Application Specific Integrated Circuits (ASIC’s). As 
mentioned, designing a SoC system where the processr, memory and all peripheral 
components are housed on the same silicon chip is very complex to design. But some Indian 
firms have been able to enter this design market as well. 
There are many Indian companies involved in module design, for customers in India as well 
as overseas. This involves designing a multi-component circuit implemented on a printed 
circuit board. If design services provided to Indian firms are included, then module level 
design is the area in the embedded services industry that has the highest volume of work by 
revenues. For example, there are thousands of smallmodule design and fabrication firms that 
cater to the domestic automobile, consumer goods an process industries.  
System Level Design is a core activity for OEMs like Nokia, IBM, Cisco, and Samsung. 
Hence it is typically not outsourced. There do exist large global technical services consulting 
firms that assist these manufacturers in designing ew systems, but very few Indian firms are 
not engaged in either creating new systems like hand-held devices or mobile phones, nor are 
they active participants in the design of these servic s, for which they need to be much closer 
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to the end consumer. However, there are some examples of firms like Sasken and Tata Elxsi, 
building and licensing entire system level designs, like Sasken’s model development services. 
However, this represents a very small segment of the work done by Indian embedded services 
firms. The simputer was an example of a domestically designed system, but Indian firms have 
made few similar forays into system design.  
 
It is important to note that each of the three design services markets (Device, Module and 
System), has its own value chain of activities. India  firms operate in each service market, 
but the extent of participation across the value chain differs. A detailed exploration of the 
Device Level Design Services Market suggests that there is potential for Indian companies to 
participate in the value chain as a lot of work is being outsourced (Goyal and Sharma, 2004). 
 
The development of the Indian IC design industry began in the early 1980’s, when Western 
semiconductor firms felt a requirement to augment tchnical staff on their in-house design 
teams. This resource augmentation goes by the familiar term called ‘body-shopping’. From 
those early days, the services industry has matured to the extent that several chip design 
projects have been completed entirely out of India. Three types of participants have emerged 
in India, to provide IC chip design services: 
 
• Global Major’s Captive Firms (TI, Intel, Analog Devices) 
• Large Design Consultancy Firms (Wipro, Tata Elxsi, Sasken, Mindtree) 
• Small Niche Design Firms (Wavelet Technologies, eInfochips) 
 
Global Major’s Captive firms usually provide design services that are higher in the value 
chain, than the large Indian design consultancies, and smaller niche design firms. All IP is 
owned by the MNCs and any patents for new chip design, or embedded software are typically 
in the USPTO. Large Design Consultancies and smaller niche design firms have not been 
able to participate across the design value chain to the same extent as the global major’s 
captive units. Moreover, the Large Design Consultancies and smaller niche design firm 
segments differ in their approach in three different ways: 
  
1. Firstly, the larger consultancies have skills across a wider range of processor platforms 
and embedded software domains.  
2. Second, the large design consultancies are increasingly trying to span the design value 
chain from specification to silicon as it is referred to by the industry. This means that 
rather than target business in one or two activities in the chip design value chain like 
design verification, or logic synthesis, these firms are trying to execute projects where 
they can become involved in architecture definition, RTL Design, Verification, and 
Physical design.  
3. Third, the larger design consultancies are also trying to create products in the form of 
packaged reusable design modules, also called as Silicon Intellectual Property (SIP), from 
the experience gained in service projects. SIP can be licensed to large OEM customers to 
accelerate the design cycle for these customers.  
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The large design consultancies have been successful in executing the first part of their 
strategy, because the sheer size of their engineering talent enables them to cover most 
processor and embedded software domains. Thus, they ar  horizontally spread across 
multiple embedded software and processor domains and provide a particular type of service 
in the value chain to their customers. The second and third elements of their strategy require 
them to go deeper into the value chain of design services, which has been a major challenge 
for them barriers to entry are not easy to transcend.  
 
A review of the history of chip design services by Indian firms suggests that over the last 
decade, they have met limited success in participating across the value chain. Third party 
design services firms, including Indian firms have found it very difficult to participate in the 
front-end design portion of the chip design value chain, by receiving outsourced design work 
from established ASIC firms like TI, IBM, and Intel. The first exposure Indian design 
services firms had to VLSI/ASIC chip design took the form of resource augmentation, 
commonly referred to as body shopping, in the late 1980’s. Design teams at large ASIC firms 
like TI, that were working on a new chip were someti s short-staffed, and required resource 
augmentation in the form of trained engineers. However, in this“sub-contracting” process the 
original design always stayed with the company, and these engineers were made to sign non-
disclosure agreements. Thus, the initial exposure that Indian design engineers had to ASIC 
design was on-site resource augmentation. 
 
Outsourcing to Indian firms began in the areas of design verification and physical design as a 
cost saving measure. Front-end design outsourcing was very rare, because the semiconductor 
IC industry faces a different risk scenario, than the software industry in case design flaws are 
revealed after the chip has been put into production.8 Therefore, outsourcing was resorted to 
only for those parts of the design chain that are less risky. Also, front-end design was an 
activity that was rarely outsourced, because it was the core strength of the ASIC firm 
developing the product, and most of the intellectual property for the chip was encapsulated in 
front-end design, hence firms performed this task in-house, while help was taken from third 
party design firms in physical design, and design verification. These are repetitive tasks, 
which are automated to a great degree using EDA tools. Economics, rather than skill played a 
major part in India receiving much of this work. After the initial round of outsourcing, 
involving mainly physical design and verification, Indian firms started to obtain work 
involving some front-end design. The work that came India’s way initially was sustenance 
work or maintenance work. This involved providing support engineering (such as 
incorporating a new standard in the design) to the c ip after it has been put in production. 
Through the early to late 1990s Indian firms that were recipients of outsourced work in 
physical design, and chip maintenance gained from this work and accumulated a track record 
of reliable services and trained man power. During the semiconductor boom in the late 
1990’s, several Indian engineers were trained on US client sites, and subsequently returned to 
India, bringing with them valuable skills and experience. Due to these factors as well as low 
                                               
8 Unlike software, where a bug-fix patch can be quickly installed, in hardware, such fixes involve product 
recalls, changes in design, and manufacturing, at a huge cost to the ASIC firm. 
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cost, when ASIC firms began to move to the next generation of a chip, or a completely new 
chip, they began to increase their reliance on India  outsourcing partners, helping the Indian 
firms move up the value chain.  
 
Currently, Indian chip design service firms are recipients of outsourced work involving all 
aspects of the design life cycle from specifications to silicon in certain commodity chips, like 
modems, USB, and Ethernet chip. These chips have to conform to certain IEEE global 
standards. They are used in a wide array of consumer electronics items, whose manufacturers 
may not be interested or skilled in designing and manufacturing them. The risk involved in 
outsourcing the development of these chips is not very high for an equipment manufacturer, 
because in case the project fails, back-up options n the form of off-the-shelf chips are 
available, although these need to be customized, an cost more. Despite all this progress 
however, in the near future, it seems unlikely thatcompanies like TI, and Intel will outsource 
the front-end chip design activity to third parties, in India or any other country including the 
US. However, these companies have opened captive cent rs in India, where the quality of 
work that is being outsourced is much higher in the value chain of chip design.  
 
The strategy followed by design services firms that are near the ASIC firms in markets like 
the US is different from the one being followed by Indian design firms. US based design 
services firms like Silicon Logic Engineering (SLE), ReShape, Qthink have moved away 
from trying to span the value chain, and re-focused th ir efforts on specific design tasks. This 
was necessary as ASIC design became very complex, and specialists were needed to handle 
specific tasks. Thus, firms that started out as small ASIC design firms spanning the value 
chain, sharpened their focus onto one specific step. At the same time, these firms invested in 
R&D for these steps and developed proprietary software tools to assist them perform these 
specialized design tasks for their customers. Indian firms have not made similar investments 
in R&D of individual steps in the design value chain. On the other hand, their strategy calls 
for them to expand their presence across the value chain. There are firms in the US that have 
followed a similar strategy of spanning the value chain of design. But the competency these 
firms bring is that of being nodal firms responsible for coordinating the design tasks of 
specialized firms on behalf of the client ASIC firm. The firm eSilicon, for instance, provides 
a design service that gives customers choices for the foundry, packager, and the like. The 
company handles all the coordination of effort and provides the oversight expertise that 
customers may lack. eSilicon does not try to play an active role in design tasks. These 
practices of US based design services firms reflect the nature of the chip design value chain 
as a set of specialized complex tasks, with front-end tasks handled by the ASIC firms in-
house, and physical design/verification tasks outsourced to specialty firms with their 
proprietary automation tools. In such a context, it would seem that Indian firms neither have 
the R&D muscle to develop proprietary tools for specialized design tasks, nor the nearness to 
customer and relationships to coordinate and integrate the workflow on behalf of the ASIC 
firm.  
 
But as chip densities increase and the resultant complex designs would require several teams 
to work in parallel on blocks of the design, and a need for continuous real-time coordination 
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among the tool developers, library, SIP, and design- ervice vendors, as well as foundries and 
process developers. This combined with the ned to accelerate the design process may seem as 
an opportunity for Indian design firms to get a part of the design pie, however, the need for 
close coordination means that Indian design teams will have to work on-site, as opposed to 
using the traditional outsourcing model, thereby losing the low cost advantage. Also, the 
industry has already seen some consolidation. For example, tool vendors are acquiring SIP 
and design-service vendors in order to tighten relationships as well as to expand their base 
businesses. It seems that large EDA vendors like Cadence stand to gain the most from these 
developments.  
 
Overall, the barriers to move up the value chain for Indian firms stem from the risk and costs 
associated with flaws in front-end design that may be uncovered after the chip is put into 
production. This prevents large ASIC firms from outsourcing this key task. Besides, front-
end design is a complex activity that represents a core competence of these firms, and they 
prefer to keep this intellectual property tightly guarded. However, intellectual property rights 
protection was not identified as a key deterrent to increased outsourcing, as most IPR’s are 
acquired in the US, and are not easy to reverse engin er in the semiconductor design industry. 
Also design services firms sign non-disclosure agreem nts with ASIC clients to protect any 
trade secrets revealed to the design services firms.  
 
3.2 IP Licensing as a Business Model 
The IP licensing business model was identified as the third element of the Indian firms 
potential strategy.  This might emerge as an interes ing option for Silicon IP (SIP). As 
mentioned earlier SIP refers to reusable design modules that can be licensed from IP vendors, 
and incorporated into a device design. Use of SIP has accelerated because semiconductor and 
systems firms are under increasing pressure to accelerat  their design process. While 
semiconductor fabrication technology as predicted by Gordon Moore has advanced rapidly, 
design capability and capacity has lagged. This is known as the design-productivity gap. 
Attempts were made to bridge this gap when specialized electronic development automation 
software tools were developed in the early 1980’s. However, the complexity of end user 
applications has resulted in an increase in the complexity of device designs, and the design 
productivity gap has only widened. The IP licensing model is seen as the next big hope in 
bridging this gap. The emergence of System-on-Chip paradigm (SoC) has given a further 
boost to the development of the licensable IP market. SIP is critical for the design and 
implementation of complex system ICs and can potentially provide a solution that enables 
companies to bridge the “design gap”. 
 
Despite the hurdles mentioned above, some Indian firms have developed a portfolio of 
reusable components that they license to chip design firms. For example, several Indian 
design firms like Wipro, Sasken, Mindtree Consulting license IP’s based on standards like 
Bluetooth, USB, WLAN, MPEG, JPEG, etc. To understand the position of Indian firms in the 
IP Licensing Value Chain, it would be useful to review the types of IP that are licensable in 
the semiconductor industry.  
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SIP products are generally available in two forms - oft and hard9. Indian firms license 
mainly Soft SIP, as they have limited access to foundries, and their skills in hardware 
definition languages and embedded software are moreature. Within this they have focused 
mainly on standards-based connectivity SIP which helps in the revision of the standards, 
which may be continuously evolving. Software IP also refers to reusable Hardware 
Dependent Software (HDS) components ranging from embedded OS, wireless stacks, and 
application software, drivers, assemblers, compilers, and multimedia codecs. Indian firms 
like Wipro, Mindtree, Sasken are strong in software SIP. In DSP software SIP, several Indian 
firms market software compression/decompression code based on established ITUT standards. 
Indian companies did not develop the baseline compression/decompression algorithms, but 
these algorithms need to be optimized to a certain DSP processor, for which knowledge of the 
instruction set and design of the DSP processor is necessary. Other forms of embedded 
software in which Indian firms are strong include providing connectivity software and 
wireless protocol stacks as per the Bluetooth Specification. Indian firms are licensing these 
software-based SIP’s extensively. Besides, some Indian firms like eInfochips are also 
licensing Verification SIP, which are essentially reusable components containing test suits for 
protocol-based designs. The verification components are configurable, reusable plug-and-
play solutions for standard interfaces based on Hardw e Verification Language. These 
verification solutions reduce the time to create the verification infrastructure.  
 
It is common in the industry to develop custom-built SIP through a service contract and 
subsequently offer it as stand-alone product when it matures. Once the SIP matures, it may be 
classified as a “commercial” product that is offered with technical support, including 
maintenance updates when the foundry design rules change or when re-characterization is 
required due to process changes. Firms have implement d effective appropriability strategies 
to protect rents from their knowledge assets. Not only have they used legal intellectual 
property protection where possible, but also harnessed other mechanisms such as rapid time-
to-market, complementary capabilities in sales and support, and network effects.  Although 
the SIP Licensing Industry has grown after 2000, despit  a downturn in the semiconductor 
industry between 2000 and 2003, Analysts and industry insiders believe that the third-party 
IP model has only limited potential, with the success of that approach confined to a few 
companies that either can offer "Star IP'" or can withstand the highly competitive market for 
commodity IP. 
 
Some Indian firms are, however, are positive about their participation through licensing and 
sub-contracting in the embedded space. The primary driver for the demand for IP Licensing 
for Indian companies has been the increased amount of software that is being embedded onto 
devices, which earlier was hardwired into chips. This is especially true for mobile handsets, 
3G Network Infrastructure, and wide area network communication stations. In these areas of 
technology, communication protocols have been standardized by international bodies like the 
IEEE, ITU, 3GPP, MPEG/ISO, ATM Forum, DSL Forum. These communication protocols 
can be implemented in hardware if speed is of essence, or they may be implemented using 
                                               
9 Goyal and Sharma (2004 provide details of different types of SIP. 
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embedded software. With increasing complexity of the algorithms that go into some of these 
standards, software implementations of standards are on the rise. For India firms, this 
development is increasing opportunities in software IP licensing. The emergence of System 
on Chip Paradigm has also increased the prospect for IP licensing for Indian firms. But SoC 
IP’s are typically hardware design IP’s or Silicon IP’s, which is an area where Indian firms 
have historically not been very strong. Within each category of IP’s (Software and Silicon), 
there is a hierarchy that separates star IP’s from c modity IP’s. Besides, the software IP 
licensing business has a significant gestation period before an IP can gain market acceptance, 
and undifferentiated IP’s bring in little revenues.  Moreover, most Indian firms seem to be 
engaged in the development of optimization algorithms, the appropriability of which (and 
consequently the revenue streams) are limited to the first time they are licensed.  
 
4. Emerging Entrepreneurial Opportunities and IPR Regimes 
The IP regimes typically have to deal with a tr de-off between invention and diffusion of 
technologies. Very stringent IP regimes can reduce the opportunities for building on existing 
technologies. It is also a well-known fact that effectiveness of IP regimes is often dependent 
on other complementary regulatory arrangements. For example, policies that permit anti-
competitive behaviour based on IP based monopolies can inhibit licensing and cross-
licensing arrangements reducing the potential of technology diffusion. The debate on the 
Microsoft case in the US provides ample evidence on the relevance of such linkages. 
 
The discussion above has highlighted the fact that with the convergence of technologies 
sectoral specificity of IP protection is breaking down. For example, IP protection in 
pharmaceutical and biotechnology sectors is no more pat nt centric. Given the ingress of IT 
based technologies, the IP protection in this sector has to deal with issues relating to patents, 
copyrights and integrated circuits protection. For example, new inventions in bio-informatics 
technologies are quite important for the cost of drug discovery. Similarly, the scope of IP 
protection in the IT sector is no more restricted to copyrights.  
One may therefore need to understand the complex int rplay between traditional patenting, 
software patenting, copyrights and integrated circuit protection.  
 
In general, therefore, for any sector one needs to analyze the role of various types of IP in the 
protection of one's inventive activity. The protection of research databases, for example, is 
emerging as a very critical element in pharmaceutical research worldwide.  The discussion 
also identified the emerging possibilities of research and production networks in the sectors 
we have identified, particularly in pharmaceuticals nd biotechnology. The IT industry in 
India already has significant exposure to inter-firm networks. But the nature of these 
networks is likely to change with a higher focus on value-adding research activities.  
 
Instead of focusing on all aspects of the new IP regim  in India, we focus on a few 
contentious issues relating to the biotech-pharma and IT-electronics sectors. In the case of 
pharma-biotech sectors questions have been raised about the patentability of new uses of 
existing chemical entities, new drug delivery mechanisms and dosage forms. In addition, 
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protection of clinical trials data (data exclusivity) has raised some concerns. In the context of 
the IT-electronics sectors, the debate has revolved around patentability of business models 
and algorithms. 
 
In what follows, we review these issues in the context of changes in technology and industrial 
structures discussed above and in view of recent changes in IPR regimes elsewhere. 
 
4.1 IPRs in the Pharmaceutical-Biotech Sector 
Among others, the following are excluded from patentability in the new patent law in India. 
These have significant implications for the pharmaceuti als and the biotechnology industries: 
 
• A mere discovery of any new property or mere new use for a known substance or of the 
mere use of a known process, machine or apparatus unle s such known process results in 
a new product or employs at least one new reactant; 
• A process for the medicinal or other treatment of human beings and animals; 
• A mere discovery of a new form of a known substance, which does not result in the 
enhancement of the known efficacy of that substance  
 
The Indian law, therefore, does not allow patents for new uses & therapeutic methods patents 
and seem to put significant constraints on the patent bility of new dosage forms & drug 
delivery mechanisms. We saw in the earlier section that very few Indian firms are actually 
engaged in the discovery of new chemical entities; most are engaged in incremental 
inventions. Such a research strategy makes sense given that R&D costs of the pharmaceutical 
industry are on the rise. The development of this research strategy has been largely attributed 
to factors like increase in number of known pharmaceuti al compounds over the years, 
knowledge of their toxicological profile and increas  of standard of life sciences in the last 
four decades.  Besides being cost-efficient and time saving, such new uses are easier to obtain 
regulatory approval than conventional new molecular entities. And this is a worldwide 
phenomenon; during 1989-2000, only 35% [361] of all the drugs [1,035] approved by the 
Food and Drugs Administration in the United States consisted new molecular entities or 
drugs consisting new active ingredients (NIHCM, 200). The remaining 65% of drugs 
contained active ingredients that were already avail ble in marketed products. Out of these, 
558 drugs differed from the marketed product in dosage form, route of administration, or 
were combined with another active ingredient. Given these trends, the US and Europe were 
compelled to protect this investment through patents. 
 
4.1.1 Issues Relating to New Use Patents – The US and European Experience10 
The European Patent Office grants new use patents but makes a distinction between 
discovering a new use of a known substance [not known t  be a pharmaceutical substance] 
and discovering a new use of a known pharmaceutical substance. The former is termed as 
first medical indication and the latter subsequent medical indication.  
                                               
10 This subsection is essentially based on Nagarsheth (2005). 
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To the former, product patent protection is granted; the EPO treats them like any new 
molecular entity. Only a method/use patent is granted to subsequent medical indications.  The 
EPO requires higher standards of utility and discloure for granting such use patents. The 
EPO Guidelines state that mere pharmaceutical effect does not necessarily imply therapeutic 
effect. It requires the patent application to state th  therapeutic application in form of a 
defined and real treatment of a pathological condition. The breadth of patent claims 
disclosing subsequent medical indications are limited to the specific new use that is disclosed 
in the patent application. If a patent applicant intends to include more than one new use in a 
patent application, the patent applicant must clearly mention each one of them in the 
application. New use is broadly defined. Basically, if a compound manages to treat a new 
disease, the EPO would consider such uses novel. Furthermore, use of the same compound 
for a different class of patients or a new way of administering the drug also seems patentable.  
 
Unlike the European law, where product patent is granted to known substance for the first 
new medical use and use patent for any subsequent us s, the US law does not distinguish 
between first medical use and subsequent medical uses of a known compound. The US law 
permits only use/method patents for known substances on grounds of lack of novelty and 
non-obviousness.11 If the known substance is commercially applicable only for the purpose 
that is laid down in the process patent, such a known substance is regarded to be a ‘non-staple 
article’ and the patentee can bring action for contribu ory infringement against an alleged 
infringer for making and selling such a non-staple article.  
 
Furthermore, if the patentee makes a slight change to the structure of the known substance 
that has a new use, product patent could be granted as long as it is non-analogous and 
complies with other requirements of patentability like novelty and non-obviousness.  A 
unique incentive is also afforded to drug companies in the United States to incrementally 
innovate through the Hatch-Waxman Act. In case of branded drugs getting approved from the 
FDA, the modified version of the branded drug on the basis of new clinical studies, would 
receive three years of market exclusivity on ‘the new use’ of the product, beginning on the 
date of the approval. ‘New use’ in this context encompasses not only new indications but also 
other changes like dosage forms, method of administering the drug and incorporating a new 
combination drug. During these three years, no generic company can market a product that is 
directly competing with this new use. Thus, by modifying the same drug repeatedly, a brand 
manufacturer may be able to keep directly competitiv  generics off the market for a decade or 
more after the compound patent on the drug has expired. Furthermore, in cases of incremental 
innovation with no new use [for instance, less side eff cts or different mode of administering 
drugs], state governments who regulate pharmacy practice encourage pharmacists to 
                                               
11 The rule that no product patent may issue for discovery of a new use for an old product or process is tempered 
by the ‘doctrine of slight changes’. It has been commented that so long as the old product has been altered 
(however slightly) to fit the new use discovered by the inventor, there is no novelty bar to obtaining the patent. 
Furthermore, the altered product may be patented if the discovery f new use and alteration when considered 
together indicate ‘invention’, that is, non-obviousness. If the new use is merely analogous to the known 
product’s known use, then generally the discovery will fail to meet the standard of non-obviousness. 
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prescribe new version of the old drug. Hence, it isapparent that the regulatory laws and the 
patent protection play an important supporting rolein fostering incremental innovation within 
the pharmaceutical industry.  
  
The US law clarifies that discoveries of natural and inherent chemical or biological 
properties per se is not a new use invention. Thus, inventions that use same compounds for 
treating same disease but which merely discloses a new natural or inherent biological or 
chemical property of the substance are not patentable.  Like European law, the US law also 
permits patents where the new use is not in discovering treatment for a new disease, but for a 
new class of patients.  New modes of administering a drug can also be patented.  
 
4.1.2 Appropriate Options for India 
Admittedly, MNCs are on the forefront in discovering new uses of pharmaceutical 
compounds. The regulatory environment in the US and Europe seem to have facilitated such 
a research strategy. This strategy appears to be cost-efficient and less risk-prone, and slowly 
Indian pharmaceutical companies seem to be getting into this strategy and therefore may gain 
from grant of new use inventions. It is not known if such a strategy would become more 
common or if Indian firms would be able to compete with MNCs, It is clear, however, that 
banning patentability of new use inventions outright would at the margin lower incentives for 
Indian firms to engage in such research.  
 
On the face of it, grant of patents for new uses of old drugs seems advisable. However, a 
strict test of Novelty and Inventive Step while assessing such inventions is also desirable.  
Given that the new Indian Patents Act does not allow patents to processes for medicinal and 
other such therapeutic treatments, claims relating to dosages, methods of administering drugs, 
patient groups, mere new knowledge of biological or chemical mechanism without any 
technical effect or improvement and new advantages to known use can be disallowed. It is 
advisable, however, that the new drug delivery system  (NDDS) that are patented have a 
significant inventive step and are not frivolous. It is not entirely clear how the efficacy of new 
NDDS and dosage forms would be determined.12 These changes would create more options 
for Indian firms to participate in drug development research and utilize licensing and cross-
licensing options. This will also create a better atmosphere for contract manufacturing of 
patented drugs and collaboration of Indian firms with MNCs in drug development activity. 
Given that laws of developed economies on new use inv ntions are not similar, it is less 
likely that such restrictive approach to new use inventions would fall foul to Article 27.3 of 
the TRIPS Agreement.  
 
The Indian Patent Act has rightly incorporated the “Bolar” Provision, that effectively allows 
manufacturers to begin the research and development process in time to ensure that 
affordable equivalent generic medicines can be brought to market immediately upon the 
                                               
12 The admixtures are currently non-patentable under the Act. It is not clear how this would affect patentability 
of NDDS and dosage forms. To the extent that this prevents the patenting of inventive NDDS, this should be 
amended. 
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expiry of the originator product’s patent. The efficacy of this provision is dependent on early 
availability of clinical trials data.  Data exclusivity rules, therefore, should not be stringent. 
Duration of data exclusivity should be amended to all w the effective scope of patent 
protection to be limited to 20 years. MNCs and some Indian associations of pharmaceutical 
companies (OPPI) have sought amendments to the Drugs and Cosmetics Act to include a 
provision of Data Exclusivity for a period of six years from the date of marketing approval. 
Data Exclusivity on research data provided in order to secure marketing rights on 
pharmaceuticals is considered important by these players as it takes up to 10 years of time 
and investment to generate such data, which provides an important competitive advantage.  
Having no data exclusivity may not be TRIPS compatible but a shorter period of data 
exclusivity at this point of time would be desirable for the Indian firms. Short periods of 
exclusivity would also enhance the utility of the Bolar provision. However, such a change 
falls outside the purview of the Patent Act. 
 
4.2 IPRs in the IT-Electronics Sector 
Our discussion in the last section showed that in the semiconductor and embedded services 
industry the critical success factors in the SIP licensing business seem to be: 
 
• Rapid time to market the IP (especially commodity IP’s) 
• Developing proprietary IP which can become a de-facto standard (Star IP’s) 
• Breadth of SIP portfolio (ability to bundle several IP’s in one license) 
• Ability to support Licensed IP 
• Strength of Relationships with Customers of the IP’s 
 
With respect to the role of intellectual property in appropriability, the impact varies 
depending on the sub-segment within the semiconductor industry. Intellectual property rights 
protection through patents and copyrights is very important for vendors of entire systems like 
computer and mobile phones, or chipsets for such vendor. Patenting is also important for 
developers of star IP’s like the ARM embedded processor, which go on to become de-facto 
standards for the rest of the industry. But for developers of commodity IP’s the critical 
success factors listed above play a much more important ole compared to IP protection. In 
the Hardware and embedded software design services indu try, IP protection is not a critical 
factor for appropriability. These firms use standard components and build applications for 
which they can use mainly copyright protection of circuit designs and embedded software 
code. Indian firms mainly operate in the Services and commodity software IP space. But 
Indian IT firms seem to be in favour of stronger IP regimes.  Recently, the Ministry of 
Industry, Government of India, organized discussion  the new IP regime with several 
stakeholders including industry associations to seek inputs on the modifications of the IP 
regime. Interestingly, in many cases, the industry associations sought more stringent IP 
regulation (Basant, 2004). In this subsection, we discuss some of these in the case of IT 
related IP. 
 
Among others, the exclusions from patentability in the new Indian patent law include: 
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• A mathematical or business method or a computer programme per se or algorithms 
• A mere scheme or rule or method of performing mental act or method of playing game 
• A presentation of information 
• Topography of integrated circuits. 
 
Since there is a separate sui generis protection for integrated circuit design, these exmptions 
imply that software per se is not patentable; although software together with hardware 
enabling the machine to function effectively may be protected. The industry associations 
have, however, argued that there is a need to bring software into the fold of patentability for 
the following reasons: 
  
• Copyright was designed to protect, with some exceptions, non-functional matter, whereas 
software or computer based business models are clearly functional works of technology. 
• Copyright does not protect ideas, methodologies, processes, techniques and the like, 
which are often the most important features of software programmes and business 
models. 
• While copyright only exists in the expression of an idea, a patent could be said to grant 
exclusive rights in the idea itself (provided that such idea can and has been tangibly 
expressed) thereby precluding others from exploiting a patented invention even if such 
invention has been developed independently. 
• Copyright and patent protections are not mutually exclusive. Patents protect creative 
functional invention whereas copyright protects creative non-functional authorship.  
 
Clearly, these arguments are significantly influenced by the IP regimes in the West, 
especially in the US. The recommendation was to revisit the clause that mathematical or 
business methods or computer programmes or algorithms per se are non-patentable subject 
matter as they may have underlying ‘technical’ principles and may easily qualify as 
technology under TRIPs. The current IP law in India provides for copyright protection for 
software. The expression/idea dichotomy used to distinguish copyrightability from 
patentability is sometimes ambiguous.  
 
The last section highlighted the fact that Indian firms do a variety of jobs – both low and high 
end. Some even get into niche areas of technology and product development and some do 
captive development. Companies in each of these segments have different concerns about the 
IP laws and their implementation.  Low-end companies are not really bothered about IPR 
laws as the work they are doing does not involve any Intellectual Property creating activity. 
Most of their work is repetitive and requires little skill. Though a situation in the future can 
be envisaged in which the companies like TCS, which ave over a period moved towards 
higher end of the product development and even creating Intellectual Property, would like to 
focus on the high end work and would in turn want to outsource their non-core activities to 
these low end companies. This would be possible when t  IPR laws in India get stricter over 
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a period of time which would give incentive to the companies like TCS, which have world 
class infrastructure and thus no longer need hand holding, to spend more on IPR generation.  
 
Strengthening of the IPR laws is also a necessity as at present, large Indian companies 
owning to majority of their business clients in US and Europe, prefer to register their IP in the 
countries where they can find big market for the products and where they are more sure of 
their IP being protected and not plagiarized. In recent times, the Indian economy has also 
started growing at a healthy rate and is projected to be one of the fastest growing economies 
along with China in the next decade. Also, more andmore MNCs that make durables like 
phones cars etc. where software is embedded are setting shop in India. Thus, in the coming 
future, these large Indian companies would no longer be able to ignore India for registration 
of their IP rights. Strong IP laws would make the MNCs comfortable in giving more and 
more business to Indian companies and even outsource higher end functions.  The same can 
be said of companies with niche products/ markets as they are always worried about their 
product/technology getting copied by competitors. This is one sector, which can clearly see 
the benefits of strong IPR laws even at present and need not look into the future for that. 
Though at present these companies prefer to register their IP rights in USA as it is the biggest 
market as well as abode for large automobile manufact ring companies, with increasing 
outsourcing to India, these companies have huge scope to build products for these companies 
which do the outsourcing work. If the products built are to be used for analytics and testing, 
then most of those products will be used by Indian companies themselves. Of course, for that, 
the companies developing the products would have to r gister their IPs in India. 
  
At the same time, services firms rarely develop proprietary technology and if they do, it often 
becomes the property of the client. Hence protection of IPR’s is usually not of much concern 
to them. They use commercially available software tools to carry out most of their design 
activities. These tools are very domain specific and would be a huge undertaking to reverse 
engineer. Hence one finds that Western firms that have developed these tools do not hesitate 
to sell their software to India firms. There does not seem to be any hesitation on the part of 
these tool vendors from doing business with Indian design firms.  In the chip design value 
chain for example, Indian firms doing physical design and design verification use 
commercially available EDA tools to provide their service. Since Indian firms have tried to 
spread themselves across the design value chain, they have not attempted to specialize in one 
activity like the US firm ReShape, which has focused on automated floor-planning solutions 
in chip layout design. By staying focused on one task of the value chain and investing in 
R&D to realize improvements in that task across multiple customer engagements, companies 
like ReShape have succeeded in developing their ownproducts.  Usually product-based 
companies have more to gain from strong IP protection regimes.  
 
Overall, while there is limited need for IP protection but it may increase in the future.  In 
India, software “per se” is not patentable although software together with hardware enabling 
the machine to function effectively may be protected. In practice, it seems many software 
patents are filed using the “embeddedness in hardware route. Article 52 of the European 
Patent Convention (EPC), and the practice that evolv d by the European Patent Office (EPO) 
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can be used as an indicator of how Indian courts will interpret the meaning of “per se”, which 
is akin to the phrase “as such” in EU law. Although the EPC does not define the term “as 
such,” the case law has developed a workable definition of the term, which allows almost all 
kinds of programs that cause a “technical effect” to be patented. A program is considered to 
have a technical effect if it causes an effect that goes beyond the “normal” physical 
interactions between a program and a computer. One such example is a computer program, 
which decodes electronic signals more accurately to provide better relay.  If this is going to 
be the interpretation, one does not see any need to have a provision wherein software p r se is 
patentable. Most of the inventions covered in Appendix II and discussed in the last section 
should be covered with this interpretation and at the same time one would be able to avoid 
business method patenting, which is desirable. 
 
The Indian software and semiconductor design industry has had a focus on services, as 
opposed to the design of complete products and systems. By the very nature of their work, 
services firms are not as affected by the IPR regim. The main concern for the services firms 
is movement of people across firms, and the possibility that trade secrets of one Western 
complete systems firms get passed on to another such firm or to a domestic Indian firm 
through employees compromising on exit clauses calling for secrecy, when they join a new 
firm. The slow legal system encourages these firms and their new employers from stealing 
trade secrets with impunity. Hence a speedier system of handling infringement suits will put a 
check on this IPR violation. A more distant possibility is the emergence of Indian firms 
designing complete systems for the domestic market. Pr ssure to enact stronger IP protection 
and better prosecute IP infringement lawsuits may come from an unexpected quarter: 
Western Governments and Industry Associations of Western manufacturers. It is in the best 
interests of India to put in place a more robust system of enforcement before the Indian 
market reaches a level of maturity where IPR infringements start to dominate the headlines. 
 
Thus, while the laws themselves seem appropriate, the lax enforcement (due to the absence of 
special patent courts) weakens the impact of the overall IP regime. As the IPR enforcement 
regime languishes, design services firms have not sto d idle. To assuage the concerns of their 
Western Clients, they maintain strong adherence to non-disclosure agreements signed with 
clients when a contract is entered into. Based on the review of the IT-Electronics industry, 
and the IP practices, a change to make software patentable does not seem to be necessary at 
this stage. However, we need to have  
 
• Better procedures in Infringement Prosecution, through special IPR courts 
• Introduction of trained IPR specialists in assessing claims, and arbitrating disputes  
 
These changes would help all sectors. This is not to suggest that Indian firms are not 
developing IP. They are but the current system seem adequate to provide regulatory support 
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to them. Creation of IP by Indian firms is desirable in order to enhance the quality of their 
linkages with other firms.13 
 
5. Some Concluding Observations 
This paper explored the recent changes in the technology and industrial structure in the global 
IT-electronics and Pharmaceutical-biotech industrie to understand the emerging trends. An 
exercise was then done to ascertain how the entrepren u ial opportunities for Indian firms 
have changed due these global changes. The final question was to assess if the existing IPR 
policies in India can potentially constrain the exploitation of these emerging opportunities by 
Indian firms.  If yes, what changes are desirable? Our conclusion is that while IP laws 
specific to the IT-electronics sector may not need any change, patentability of novel new uses 
of existing compounds and inventive NDDS is desirable. Besides, a liberal regime on data 
exclusivity would enhance the opportunities provided by the Bolar provision in the new 
Patent Act.14 An overall improvement of enforcing IPRs is certainly desirable. The rest of this 
section raises some general concerns about the new IP framework in India. 
 
 5.1 Need for Petty Patents 
Studies of IP systems in Japan and elsewhere have shown that certain features of their 
systems facilitated technology diffusion (Maskus and McDaniel, 1999). The primary channel 
of technology diffusion in Japan was derived from applications for utility “models, which are 
incremental inventions that build on knowledge in existing patent applications and that can be 
put to commercial use quickly.  (The U.S. patent system offers no equivalent to the utility 
model.)  Japanese and foreign patents were used as the bases for modified technologies.  The 
industries that most often built upon foreign patent applications and filed domestic utility 
model applications were in chemistry (including metallurgy) and the physics, 
communication, and measurement industries.  One important indirect result of initial patent 
applications was the stimulation of follow-on utility models.  All this encouraged diffusion 
that promoted “catching up” to advanced technologies. The 1994 amendments to Japan’s 
intellectual property laws streamlined the utility model application process by eliminating the 
examination (effectively ending the need for publication of the application and opposition 
procedures) and shortening the length of protection fr m 15 years to 6 years from the 
application filing date. The shortened term of protection, coupled with increased registration 
and maintenance fees, has reduced the expected value of a utility model and thus caused a 
decrease in the number of utility applications in favor of patent applications (Aoki, 1997). For 
Indian firms such an option may still be useful. It can be argued that the Indian Patent Office 
                                               
13 For Geometric Software their IP is the main differentiator as compared to other service-oriented firms. This 
ability to build IP was one of the key reasons why mainstream PLM vendors entrusted the source codes of their 
software by establishing offshore development centers in Geometric IP is also the key reason why French PLM 
major Dassault decided to enter into a joint venture with Geometric.  Similarly, Ittiam Systems has its entire 
business model based on IP licensing. In a short span of two years, the company has created a record portfolio 
of 30 IPs and 26 customer engagements. 
14 Interestingly, this policy advice is largely consistent with the views of the US venture capital firms whom we 
interviewed during the course of this project, except of course on the issue of data exclusivity where they would 
prefer a more stringent regime.  
 23 
has limited resources and such a system would put pressure on them.  There will be some 
additional burden but it may be desirable because sch patents would enhance he utility of 
the pre-grant disclosure and opposition provisions that the Indian Act has included. Now, the 
local firms would look at these applications not only from the perspective of opposition but 
for incremental innovations. Similar provisions in Japan and South Korea resulted in 
significant cross licensing between original and the subsequent (incremental) innovators. This 
in turn facilitated learning and diffusion of patent d technologies. The utility of this provision 
would get enhanced if the claims are narrowly defined, a feature all patent systems should 
work towards.15 
 
5.2 Amendments in Compulsory Licensing: 
The current IP laws in India, at any time after theexpiration of 3 years from the date of 
sealing of a patent, any interested person can make an application to the Controller for a 
Compulsory License on any of the following grounds:  
 
• Reasonable requirements of the public with respect to the patented invention have not been 
satisfied. 
• The patented invention is not available to the public at a reasonably affordable price. 
• The patented invention is not worked in the territoy f India.  
 
While the first clause makes sense, the other two can be problematic. It is not clear if the last 
clause is TRIPS compatible. Using a price criterion while Drug Price Control Order is TRIPS 
compatible seems superfluous and makes the interpreation of “reasonably affordable price” 
quite cumbersome. Surprisingly, the provisions on compulsory licensing deem specific 
instances of anti-competitive behavior as not satisfying “reasonable requirements of public”.  
A new clause needs to be added to broaden the scope of the first condition. This is 
particularly desirable because according to TRIPS, compulsory licensing undertaken due to 
anti-competitive practices need not have any restriction on the export of the patented product. 
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Industrial Application No and type of IP Nature of use Market JV/R&D/Tie-up 
Wipro Local 
SoC and board 
design, core IP design 
Consumer electronics, automobile, 
communications, defense 





(all for design services)/ASE (test 
packaging)/Mosis/GE/ 
Erriscson 
Sasken Local Design and embedded 
Communications, test and 
measurement 
39 patents Licensing Japan/Canada 






Communications, defense, telecom, 
networking, DSP (signal 
processing) 
225 patents Licensing U.S/Europe 
4-offcampus development 
centers/OMAP tech centers/3rd party 









55 patents  IBM/Dell/HP Analog/Sony 
Mistral Local Embedded software, 
board and chip design 
Consumer Electronics, Automotive, 
Telecommunications, Wireless, 
Networking, Defense, Aerospace, 
Office Automation, Semiconductor, 











EDA* design tools, 
design services 
Design tools, wireless 
communications 
 Sale 
IC and systems 
designers, embedded 
services 
Agilent/IITs/ IIT-Kharagpur (developed 
chipset) 
Cypress MNC Chip design, software Networking, computing, industrial 60 patents 
compiled 
   
Analog MNC 
Design and 













MNC SoC solution 




PCs, networks and a 
broad range of 
portable applications 
Collaborated with 3 Indian firms for 
localizing set-top-boxes 
Motorola MNC 









Cisco MNC Chip design Networking, Telecom 9 patents filed   Promoting development centers with 





Design tools development   
India/U.S/ 
Europe 
IIT-Kharagpur (VLSI lab)/Sasken (sub-
contracts)/ TI/ ST /Intel Wipro/DoE 
ControlNet (clients)/ Avanti (Hyderabad 
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design services acquisition) 
HCL Local Core IP design, 
software, 
Communications, Industrial Reusable 
components 
  
Magma (for design services)/Cisco, GM 
(clients)/ KLA Tencor, NCR, Convergys, 
Toshiba, Siemens VDO, NTT Data and 
Lexis-Nexis/ Deutsche Software and 
GIC (U.S) (JV) 
Interra Systems Local SoC designs, 
embedded software 
Electronics, video and memory 
applications 













Chip and system level 
design 
Communications/networking     
IBM India MNC  
Biotechnology, Computing, 
communications, networking 




Ittiam (A Texas 
spin off) 
Local 
Chip designs and 
embedded systems 
Audio-speech, image-video, 
wireless and wire line 
communication 
30- IP/2 patents 
filed 
Licensing 
US, Europe, Japan, 
Taiwan and Korea 














Mind Tree Local 
Designs re-usable 
building blocks for hi-
tech companies, 
software 
Communications   
Developed a PDA for 
a U.S client/ 
Sun (tech partner)/Walden and Capital 









100 filed and 32 
filed (2002) 




Chip design and 
software for SoC Broadband (cable/DSL)  Licensing 
Europe/US/ 
India 
Phillips Semiconductor (51% 







networking, multimedia, SoC 















Local IP blocks 







Wipro/ Dassault Systemes(partnership) 
vMoksha Local  Enterprise solution  
One patent filed 
(authentica-tion 
protocol) 
India, the UK, the 
US, Australia and 
Singapore/ 
Japan/China 
JV with Chinadotcom/ Challenger 
Systems 




MNC Fujitsu, Siemens, 
Cisco and Sony 
Semicon/UMC 
Intel MNC 
Chip design and 
manufacturer, 
embedded 
Semiconductors, telecom switching, 
equipment and routers, computing, 
communications 




Network Solutions (Acq. 
b’lore)/IITs/Thinit (acq. Blore /IISc 
TCS Local Software solution 
Banking/insurance/telecom/manufac
turing/Biotechnology 




GE India MNC  
Controllers, consumer electronics, 
transport 
   Wipro 
Sun Micro-
systems 
MNC Server design Computing, Biotechnology 10 filed   HCL/Wipro/supercomputing facility at 
IIT-Delhi 




Communications  IP creation and 
re-use 
  
Silicon Interfaces Local 








Aftek Infosys Local       





usable IP cores 
 




U.S startup  
Communications, computing, 
consumer and industrial 











Embedded, computing and 
Biotechnology 
    




Telecom, Insurance, manufacturing, 
finance, computing and 
Biotechnology 




Local Software solutions Telecom, Insurance, manufacturing, 
finance and Biotechnology    
Centre for Cellular and Molecular 
Biology (CCMB 
Infosys Local Software solutions 
Telecom, Insurance, manufacturing, 




Multimedia, Energy, manufacturing, 
defense, Biotechnology 
   GVK Bioscience (Hyderabad) 







Local Designing, computing 
Biotechnology, communications, 
computing, networking 
    
EDA*= Electronic Design Automation that automates the process of IC and systems designs. 
Core IP* design = It is a chip design that can be us d as a core in almost all product development. 
